Metformin inhibits angiogenesis of endothelial progenitor cells via miR-221-mediated p27 expression and autophagy.

Hai-Zhen Ni,Zhao Liu,Li-Li Sun,Min Zhou,Chen Liu,Wen-Dong Li,Xiao-Qiang Li
DOI: https://doi.org/10.4155/fmc-2019-0017
2019-01-01
Future Medicinal Chemistry
Abstract:Aim: To explore the underlying mechanisms of metformin on the angiogenic capacity of endothelial progenitor cells (EPCs). Results: EPC growth and miR-221 expression decreased concentration-dependence with metformin, and a negative correlation was observed between miR-221 expression and metformin concentration (p < 0.001). miR-221 overexpression using a mimic decreased the metformin-mediated angiogenic effects in EPCs (p < 0.01). Metformin increased p27 and LC3II expression and AMP-activated protein kinase (AMPK) phosphorylation, and decreased p62 expression, while miR-221 overexpression reversed the effects of metformin. Additionally, AMPK inhibition by compound C reversed the increase in p27 and LC3II levels and AMPK phosphorylation or miR-221 siRNA treatment. Conclusion: Metformin inhibits the angiogenic capacity of EPCs. The underlying mechanism involves AMPK-mediated autophagy pathway activity and increases miR-221-mediated p27 expression.
What problem does this paper attempt to address?